<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="1453">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 10, 2022</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04093882</url>
  </required_header>
  <id_info>
    <org_study_id>BHSkog</org_study_id>
    <nct_id>NCT04093882</nct_id>
  </id_info>
  <brief_title>The Relevance of the Blood-brain Barrier to Cognitive Dysfunction and Alzheimer's Disease</brief_title>
  <official_title>The Relevance of the Blood-brain Barrier to Cognitive Dysfunction and Alzheimer's Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Charite University, Berlin, Germany</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Prof. Dr. med. Jochen Fiebach (Senior Physician)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Charite University, Berlin, Germany</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study attempts to replicate the findings published in Nature Medicine by Nation and&#xD;
      colleagues (2019). By using a large observational cohort (DZNE - Longitudinal Cognitive&#xD;
      Impairment and Dementia Study; DELCODE) consisting of cognitively healthy individuals,&#xD;
      individuals with subjective cognitive decline, mild cognitive impairment, and dementia due to&#xD;
      Alzheimer's disease, an association between the blood-brain barrier and cognitive dysfunction&#xD;
      is investigated. The integrity of the blood-brain barrier is investigated by using a novel&#xD;
      MRI protocol as well as a novel biomarker in the cerebrospinal fluid.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 12, 2019</start_date>
  <completion_date type="Actual">September 30, 2021</completion_date>
  <primary_completion_date type="Actual">September 30, 2021</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <target_duration>1 Day</target_duration>
  <primary_outcome>
    <measure>Marker of blood-brain dysfunction using MRI</measure>
    <time_frame>1 day</time_frame>
    <description>Dynamic T1 contrast enhanced sequence using Gadovist</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Markers of blood-brain dysfunction using CSF</measure>
    <time_frame>1 day</time_frame>
    <description>Platelet-derived growth factor receptor-β in CSF</description>
  </primary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Actual">101</enrollment>
  <condition>Blood Brain Barrier</condition>
  <condition>Alzheimer Disease</condition>
  <condition>Cognitive Dysfunction</condition>
  <condition>Dementia</condition>
  <arm_group>
    <arm_group_label>Cognitive normal</arm_group_label>
    <description>Individuals who do not show clinical or neuropsychological deficits.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Mild cognitive impairment</arm_group_label>
    <description>Individuals who show deficits in neuropsychological test procedures but who do not exhibit substantial problems in daily life. Those individuals are part of the DELCODE cohort and were initially recruited in a memory clinic.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dementia due to Alzheimer's disease</arm_group_label>
    <description>Individuals diagnosed with dementia due to Alzheimer's disease by relying on anamnesis, neuropsychological test results, results of MRI and biomarkers found in the cerebrospinal fluid. Those individuals are part of the DELCODE cohort and were initially recruited in a memory clinic.</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Contrast agent enhanced MRI using Gadovist</intervention_name>
    <description>By using the contrast agent Gadovist we aim to visualize the blood-brain barrier. Furthermore, we aim to measure a newly developed biomarker of the blood-brain barrier in the cerebro-spinal fluid.</description>
    <arm_group_label>Cognitive normal</arm_group_label>
    <arm_group_label>Dementia due to Alzheimer's disease</arm_group_label>
    <arm_group_label>Mild cognitive impairment</arm_group_label>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Cerebro-spinal fluid&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        A description of the study population is provided by DZNE - Longitudinal Cognitive&#xD;
        Impairment and Dementia Study (DELCODE).&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion criteria:&#xD;
&#xD;
        - ≥ 50 years with neuropsychologically confirmed no cognitive dysfunction, mild cognitive&#xD;
        impairment or mild dementia&#xD;
&#xD;
        Exclusion cirteria:&#xD;
&#xD;
          -  no current or prior history of any neurological or psychiatric condition, which might&#xD;
             affect cognitive function&#xD;
&#xD;
          -  no neurodegenerative disease other than AD&#xD;
&#xD;
          -  specifically no extensive vascular white matter dementia or vascular dementia&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Charité Universitätsmedizin Berlin</name>
      <address>
        <city>Berlin</city>
        <zip>10117</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>September 13, 2019</study_first_submitted>
  <study_first_submitted_qc>September 17, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">September 18, 2019</study_first_posted>
  <last_update_submitted>November 5, 2021</last_update_submitted>
  <last_update_submitted_qc>November 5, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 11, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Charite University, Berlin, Germany</investigator_affiliation>
    <investigator_full_name>Oliver Peters, MD</investigator_full_name>
    <investigator_title>Prof. dr. med. (Consultant Psychiatrist)</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alzheimer Disease</mesh_term>
    <mesh_term>Cognitive Dysfunction</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

